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432a Tuesday, February 18, 2014arrhythmogenic early afterdepolarizations (EADs) characteristic of LQT2 my-
ocytes under b-adrenergic stimulation. Parameters of Ca handling were
measured in ventricular myocytes isolated from normal and LQT2 hearts using
confocal Ca imaging and whole-cell patch clamp. Ca imaging revealed no
LQT2-mediated changes in amplitude of Ca transients and SR Ca content under
basal conditions. Experiments in saponin-permeabilized cells using SR-
entrapped low-affinity Ca indicator revealed enhanced RyR-mediated SR Ca
leak and SERCA-mediated Ca uptake in LQT2 myocytes. Correspondingly,
western blot analyses using phospho-specific antibodies showed that phosphor-
ylation of both RyR and phospholamban is significantly higher in LQT2 CMs
vs. controls at both PKA and CaMKII sites. In the presence of isoproterenol (50
nM) LQT2 CMs exhibited diminished Ca transient amplitudes and SR Ca con-
tent compared to controls. Stimulation of LQT2 CMs with isoproterenol re-
sulted in prolongation of plateau of action potentials accompanied by
aberrant Ca releases and phase 3 EADs, in contrast to controls. Importantly,
preincubation of LQT2 CMs with CaMKII inhibitor KN93 (10 min, 500 nM)
prevented ISO-mediated changes in AP duration, disturbances in Ca handling
and EADs. Analysis of CaMKII activity revealed no differences between
LQT2 and control heart tissues, while Western-blot analysis demonstrated
~30% decrease in the abundance of catalytic subunit of protein phosphatase
type 1 (PP1). These data suggest that hyperactive RyRs due to adaptive reduc-
tion in PP1 activity and thereby RyR hyperphosphorylation is a key contributor
to enhanced triggered activity in hereditary LQT2 syndrome.
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Intracellular calcium plays a role in a host of cellular functions ranging from
synaptic transmission to gene expression. As a transient, short-range signaling
molecule, calcium is often presented in complex signal patterns, including os-
cillations and bursts. The concerted action of pumps, channels, and buffers in
conjunction with the ion-impermeable cell membrane tightly regulates these
calcium signals spatially and temporally but simultaneously impedes our ability
to study the action of calcium. Many techniques measure changes in intracel-
lular calcium, providing insights into the specificity of these signal patterns,
but fewer are capable of controlling calcium levels in cells. Patch clamp pipette
access can be used to modulate calcium in small numbers of cells, but larger
scale control often requires disruption of normal calcium signaling using drugs
such as thapsigargin, in order to couple intracellular calcium to an external cal-
cium signal. Here we present a new technology to rapidly modulate intracel-
lular calcium. Using supported nanotubes called ‘‘nanostraws,’’ we
demonstrate direct ionic delivery into cells. The dimensions of the nanostraws
(~100 nm x 1 mm tall) allow them to spontaneously penetrate the cell, thereby
allowing calcium to bypass the lipid membrane and its constituent calcium
channels through the nanostraws. Calcium delivery is controlled by fluid
flow, and intracellular calcium oscillations can be induced and modulated in
amplitude and frequency. While previous studies have perturbed long-term
cell behavior using nanostraws and similar systems, here we apply the tech-
nique to transient signaling by rapid intracellular calcium modulation and char-
acterize the spatiotemporal delivery using calcium indicators (e.g. Fluo-4,
GCaMP6). By circumventing the intrinsic calcium regulatory mechanisms,
nanostraws provide direct access and the ability to mimic biological calcium
oscillations, adding a new method for decoding the role of calcium signal pat-
terns and their effects on downstream signaling.Platform: Ion Channels and Disease
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Cystic fibrosis (CF) is a chronic lethal genetic disease, which is caused by mu-
tations in the cystic fibrosis transmembrane conductance regulator (CFTR)gene. F508del - deletion of a single phenylalanine residue at position 508 - is
the most common lethal mutation found in CF patients. Fully synthesized
F508del-CFTR is rapidly degraded in the endoplasmic reticulum due to
F508del-induced misfolding, preventing proper transport of the protein to the
epithelial cell membrane. In previous work, we have demonstrated that
F508del facilitates partial unfolding and consequent aggregation of the first
nucleotide-binding domain in human CFTR (hNBD1). This F508del-
faciliated aggregation is likely a key contributor in F508del-CF pathogenesis.
These findings established a foundation to develop a new high-throughput bio-
physical screen to identify compounds that directly bind to the hNBD1 domain
to prevent the F508del-hNBD1 aggregation in vitro and thereby stabilize
F508del-CFTR in vivo. We used computational protein engineering to construct
an equivalently stable hNBD1 variant that reacts with a visible fluorophore
exclusively at a single labeling site. Fluorescence self-quenching of this labeled
domain upon unfolding/aggregation provides a robust assay for stabilizing com-
pounds, and this assay gives a Z-factor 0.8 in high-throughput screening. We
will describe thermodynamic and structural studies on compounds identified us-
ing this screen as well as progress in implementing an equivalent screen in
models of full-length human CFTR. Our results demonstrate that thermody-
namic stabilization of a protein via interaction of a small molecule at a site
remote from a mutation can indirectly correct a genetic defect.
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G551D, the third most common pathogenic mutation in CF, exhibits an
extremely low Po because ATP fails to increase its activity. Although
VX-770 (Ivacaftor) improves the symptoms of patients carrying the G551D
mutation, it is insufficient to completely rectify this gating abnormality. In
excised inside-out patches, we found that VX-770 increases the ATP-
independent Po of WT-CFTR by ~ 9-fold, a magnitude very similar to the
effect of VX-770 on G551D-CFTR (12.8 5 1.9 fold, n = 12), suggesting a
common mechanism of action: VX-770 simply shifts the equilibrium of
ATP-independent gating towards the open state. However, upon ATP removal
VX-770-potentiated macroscopic G551D-CFTR currents increases initially by
~2-fold (1.655 0.48, n = 3), followed by a slow decay. Such a biphasic time
course suggests two ATP binding sites with opposite effects and different affin-
ities. We hypothesize that the G551D mutation converts the low-affinity ATP-
binding site (i.e., site 2) to an inhibitory site, whereas the high-affinity site 1
remains stimulatory. This hypothesis predicts that lowering [ATP] could actu-
ally increase the G551D-CFTR current. Indeed, replacing 2 mM ATP with 20
mMATP increases the current by ~ 2-fold. To further test this idea, we mutated
W401 and Y1219, two aromatic amino acids known to interact with ATP in site
1 and site 2 respectively. While ATP removal increases G551D/W401G cur-
rents by ~ 2-fold (2.12 5 0.12, n = 8), a mono-phasic current decrease is
seen with G551D/Y1219G-CFTR. However, the relaxation time constants for
the current decay phase for G551D and G551D/Y1219 (41.8 5 1.0 s and
32.4 5 1.6 s respectively) are significantly longer than that of G551D/
W410G (28.85 0.5 s). These results point to a unique mechanism underlying
CF pathogenesis by the G551D mutation.
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Influenza A develops amantadine resistance within days in tissue culture or
infection. The amantadine-resistant mutant, M2 S31N, has become globally
dominant in human isolates. Infection of MDCK cells by a pandemic 2009
H1N1 strain, bearingM2 S31N, was blocked by low-micromolar concentrations
for a set of amantadine analogs previously shown to block several M2-WT influ-
enza strains from H1N1, H2N2, and H3N2 subtypes. Three sets of variants were
synthesized to explore SAR properties. One demonstrated that opening the
